Immunovant
IMVT
120 hedge funds and large institutions have $654M invested in Immunovant in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 30 reducing their positions, and 56 closing their positions.
124% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $6.89M
67% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 30
0.09% more ownership
Funds ownership: 41.2% → 41.29% (+0.09%)
18% less funds holding
Funds holding: 147 → 120 (-27)
48% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 56
65% less capital invested
Capital invested by funds: $1.86B → $654M (-$1.21B)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$46.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$40.6M |
| 3 |
AGM
Alpine Global Management
New York
|
+$28.9M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$26.4M |
| 5 |
Two Sigma Investments
New York
|
+$19.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$64.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$64.7M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$63.6M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$41.2M |
| 5 |
RI
RTW Investments
New York
|
-$32.6M |
IMVT Hedge Fund Activity: Q1 2021 in Review
120 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2021, worth a combined $654M — down 65% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of IMVT and 29 opened new positions — a net loss of 27 holders — while 30 trimmed existing stakes and 50 added.
The largest buyer was State Street, adding an estimated $46.1M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $64.7M sold.
- 120 institutional investors held Immunovant (IMVT) as of Q1 2021, down from 147 in Q4 2020.
- Funds reported $654M of Immunovant stock for Q1 2021, down 65% quarter-over-quarter.
- 29 funds opened new Immunovant positions in Q1 2021 and 56 closed out, a net change of -27 holders.
- The largest Immunovant buyer in Q1 2021 was State Street, an estimated $46.1M added.
- The largest Immunovant seller in Q1 2021 was Adage Capital Partners, an estimated $64.7M sold.
Based on aggregated 13F filings for Q1 2021.